Cover Image
市場調查報告書

神經內分泌腫瘤:全球臨床實驗檢討

Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014

出版商 GlobalData 商品編碼 298846
出版日期 內容資訊 英文 124 Pages
訂單完成後即時交付
價格
Back to Top
神經內分泌腫瘤:全球臨床實驗檢討 Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014
出版日期: 2014年03月31日 內容資訊: 英文 124 Pages
簡介

本報告提供神經內分泌腫瘤相關臨床研究最新趨勢相關分析,以疾病概要為首,提供地區及主要國家的臨床實驗狀況,Phase別·各進展狀況臨床實驗資料,被實驗者的募集情況,有潛力的贊助商,並且各企業·研究機關臨床實驗簡介等彙整資訊,為您概述為以下內容。

目錄

簡介

  • 神經內分泌腫瘤
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數和平均實驗人數
    • 亞太地區的主要5個國家
    • 歐洲的主要5個國家
    • 北美的主要國家
    • 中東非洲的主要國家
    • 中南美的主要5個國家

在G7各國臨床實驗

在G7各國臨床實驗:各階段

在G7各國臨床實驗:各進展狀況

在E7各國臨床實驗

在E7各國臨床實驗:各階段

在E7各國臨床實驗:各進展狀況

各階段臨床實驗

  • 進行中的臨床實驗:不同階段

各進展狀況臨床實驗

一定期間所採用的實驗對象

贊助商的不同種類的臨床實驗

有潛力的贊助商

  • 參加神經內分泌腫瘤治療藥臨床實驗的前幾名企業

有潛力的藥劑

臨床實驗簡介

  • 代表性企業臨床實驗概要
    • Novartis AG
    • Pfizer Inc.
    • Ipsen S.A.
    • F. Hoffmann-La Roche Ltd.
    • Progenics Pharmaceuticals, Inc.
    • Tekmira Pharmaceuticals Corp.
    • Threshold Pharmaceuticals, Inc.
    • Merck & Co., Inc.
    • Eli Lilly and Company
    • 第一三共
  • 有代表性的醫院·研究機關臨床實驗概要
    • National Cancer Institute
    • The University of Texas M. D. Anderson Cancer Center
    • Memorial Sloan Kettering Cancer Center
    • Stanford University
    • Grupo Espanol de Tumores Neuroendocrinos
    • University of Wisconsin Madison
    • The University of Iowa
    • University of California, San Francisco
    • Alberta Health Services

5個有代表性的臨床實驗簡介

附錄

圖表一覽

目錄
Product Code: GDHC2063CTIDB

GlobalData's clinical trial report, "Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014" provides data on the Neuroendocrine Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroendocrine Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroendocrine Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Neuroendocrine Cancer
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Neuroendocrine Cancer to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Neuroendocrine Cancer to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Neuroendocrine Cancer
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Neuroendocrine Cancer Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Neuroendocrine Cancer
    • Apr 09, 2013: ArQule's New AKT Pathway Inhibitor, ARQ 092, Demonstrates Safety, Target Inhibition in Phase I Trial
    • Oct 25, 2008: Callisto Pharmaceuticals To Open Atiprimod Phase II Extension Trial In Neuroendocrine Cancer
    • Oct 07, 2008: Neotropix Announces The Expansion Of On-going Clinical Trial For Adult Neuroendocrine Cancers
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • Pfizer Inc.
      • Clinical Trial Overview of Pfizer Inc.
      • Ipsen S.A.
      • Clinical Trial Overview of Ipsen S.A.
      • F. Hoffmann-La Roche Ltd.
      • Clinical Trial Overview of F. Hoffmann-La Roche Ltd.
      • Progenics Pharmaceuticals, Inc.
      • Clinical Trial Overview of Progenics Pharmaceuticals, Inc.
      • Tekmira Pharmaceuticals Corp.
      • Clinical Trial Overview of Tekmira Pharmaceuticals Corp.
      • Threshold Pharmaceuticals, Inc.
      • Clinical Trial Overview of Threshold Pharmaceuticals, Inc.
      • Merck & Co., Inc.
      • Clinical Trial Overview of Merck & Co., Inc.
      • Eli Lilly and Company
      • Clinical Trial Overview of Eli Lilly and Company
      • Daiichi Sankyo Company, Limited
      • Clinical Trial Overview of Daiichi Sankyo Company, Limited
    • Clinical Trial Overview of Top Institutes / Government
      • National Cancer Institute
      • Clinical Trial Overview of National Cancer Institute
      • The University of Texas M. D. Anderson Cancer Center
      • Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center
      • Memorial Sloan Kettering Cancer Center
      • Clinical Trial Overview of Memorial Sloan Kettering Cancer Center
      • Stanford University
      • Clinical Trial Overview of Stanford University
      • Grupo Espanol de Tumores Neuroendocrinos
      • Clinical Trial Overview of Grupo Espanol de Tumores Neuroendocrinos
      • University of Wisconsin Madison
      • Clinical Trial Overview of University of Wisconsin Madison
      • The University of Iowa
      • Clinical Trial Overview of The University of Iowa
      • University of California, San Francisco
      • Clinical Trial Overview of University of California, San Francisco
      • Alberta Health Services
      • Clinical Trial Overview of Alberta Health Services
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Neuroendocrine Cancer Therapeutics, Global, Clinical Trials by Region, 2014*
  • Neuroendocrine Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Neuroendocrine Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014*
  • Proportion of Neuroendocrine Cancer to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Neuroendocrine Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Neuroendocrine Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Neuroendocrine Cancer to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Neuroendocrine Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Neuroendocrine Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Neuroendocrine Cancer Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Neuroendocrine Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Neuroendocrine Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Neuroendocrine Cancer Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Neuroendocrine Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Neuroendocrine Cancer Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Neuroendocrine Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Ipsen S.A., 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Progenics Pharmaceuticals, Inc., 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Tekmira Pharmaceuticals Corp., 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Threshold Pharmaceuticals, Inc., 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Grupo Espanol de Tumores Neuroendocrinos, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Wisconsin Madison, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Iowa, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Alberta Health Services, 2014*

List of Figures

  • Neuroendocrine Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Neuroendocrine Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Neuroendocrine Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014*
  • Proportion of Neuroendocrine Cancer to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Neuroendocrine Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Neuroendocrine Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Neuroendocrine Cancer to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Neuroendocrine Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Neuroendocrine Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Neuroendocrine Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Neuroendocrine Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Neuroendocrine Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Neuroendocrine Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology

Back to Top